Loading...

JANX JANUX THERAPEUTICS INC Product Launches 8-K Filing

JNX

JNX

JANUX THERAPEUTICS INC

(JANX)

2024 8-K

Show Summary

Summary

Financial Statements

Financial Results

Public Offering

Clinical Data Update

Financial Results

Financial Results Announcement

Departure of Directors and ...

Financial Results Announcement

Financial Results Announcement

Public Offering

Suspension of Prospectus Su...

Capital Resources and Inter...

Earnings Reports

Financial Results Announcement

Equity Offerings

Results of Operations and F...

Resignation of CMO

Delisting Notice

Equity Offering

Financial Results Announcement

Departure of Directors

Financial Results Announcement

External Links:

Janux Therapeutics announced promising interim clinical data for its JANX007 program, showing high response rates in prostate cancer patients, with 100% achieving PSA50 declines and 63% achieving PSA90 declines as of November 15, 2024.

AI Assistant

JANUX THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.